Gyongyi Szabo to Biomarkers
This is a "connection" page, showing publications Gyongyi Szabo has written about Biomarkers.
Connection Strength
1.798
-
Szabo G, Momen-Heravi F. Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2017 Aug; 14(8):455-466.
Score: 0.394
-
Taiwo M, Huang E, Pathak V, Bellar A, Welch N, Dasarathy J, Streem D, McClain CJ, Mitchell MC, Barton BA, Szabo G, Dasarathy S, Schaefer EA, Luther J, Day LZ, Ouyang X, Suyavaran A, Mehal WZ, Jacobs JM, Goodman RP, Rotroff DM, Nagy LE. Proteomics identifies complement protein signatures in patients with alcohol-associated hepatitis. JCI Insight. 2024 04 04; 9(9).
Score: 0.158
-
Tornai D, Mitchell M, McClain CJ, Dasarathy S, McCullough A, Radaeva S, Kroll-Desrosiers A, Lee J, Barton B, Szabo G. A novel score of IL-13 and age predicts 90-day mortality in severe alcohol-associated hepatitis: A multicenter plasma biomarker analysis. Hepatol Commun. 2023 12 01; 7(12).
Score: 0.154
-
Szabo G, Thursz M, Shah VH. Therapeutic advances in alcohol-associated hepatitis. J Hepatol. 2022 06; 76(6):1279-1290.
Score: 0.139
-
Monnig MA, Lamb PS, Parra JM, Cioe PA, Martone CM, Monti PM, Szabo G. Immune Response to an Acute Moderate Dose of Alcohol in Healthy Young Adults. Alcohol Alcohol. 2020 Oct 20; 55(6):616-623.
Score: 0.124
-
Saha B, Tornai D, Kodys K, Adejumo A, Lowe P, McClain C, Mitchell M, McCullough A, Dasarathy S, Kroll-Desrosiers A, Barton B, Radaeva S, Szabo G. Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis. Hepatology. 2019 10; 70(4):1134-1149.
Score: 0.113
-
Moreno C, Mueller S, Szabo G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol. 2019 02; 70(2):273-283.
Score: 0.110
-
Szabo G, Kamath PS, Shah VH, Thursz M, Mathurin P. Alcohol-Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study. Hepatology. 2019 05; 69(5):2271-2283.
Score: 0.110
-
Szabo G, Csak T. Role of MicroRNAs in NAFLD/NASH. Dig Dis Sci. 2016 May; 61(5):1314-24.
Score: 0.089
-
Momen-Heravi F, Saha B, Kodys K, Catalano D, Satishchandran A, Szabo G. Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. J Transl Med. 2015 Aug 12; 13:261.
Score: 0.087
-
Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K, Szabo G. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. J Transl Med. 2015 Jun 16; 13:193.
Score: 0.086
-
Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, Alao H, Kodys K, Szabo G. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology. 2012 Nov; 56(5):1946-57.
Score: 0.070
-
Bala S, Marcos M, Szabo G. Emerging role of microRNAs in liver diseases. World J Gastroenterol. 2009 Dec 07; 15(45):5633-40.
Score: 0.058
-
Szabo G, Dolganiuc A, Mandrekar P. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology. 2006 Aug; 44(2):287-98.
Score: 0.046
-
Fan X, McCullough RL, Huang E, Bellar A, Kim A, Poulsen KL, McClain CJ, Mitchell M, McCullough AJ, Radaeva S, Barton B, Szabo G, Dasarathy S, Rotroff DM, Nagy LE. Diagnostic and Prognostic Significance of Complement in Patients With Alcohol-Associated Hepatitis. Hepatology. 2021 03; 73(3):983-997.
Score: 0.031
-
Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology. 2020 01; 71(1):306-333.
Score: 0.029